# Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance

- Link: https://www.thailand-business-news.com/pr-news/antengene-presented-first-preclinical-data-at-eular-2026-showing-atg-207-promotes-regulatory-t-cell-induction-and-immune-tolerance
- Published: 2026-06-08T07:00:00+07:00
- Author: PR Newswire

|   |

SHANGHAI and HONG KONG, June 8, 2026 /PRNewswire/ — Antengene Corporation Limited(**"
Antengene"**, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech
company dedicated to discovering, developing and commercializing first-in-class 
and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological
malignancies indications, today announced that it has presented **the first preclinical
data on ATG-207, α** **masked and TGFβRIII-biased CD3-TGF-β bifunctional fusion 
protein **in a poster presentation at the 2026 European Congress of Rheumatology(
EULAR 2026), held from June 3 to 6 at Excel London in the United Kingdom. **The 
data showed that ATG-207 preferentially binds TGFβRIII, rapidly downregulates T 
cell receptor expression on the T cell surface, induces regulatory T cells. Proteomic
analysis revealed that ATG-207 markedly modulates functional remodeling of primary
T cells. ATG-207 demonstrated potent therapeutic activity through a mouse surrogate
molecule in experimental autoimmune encephalomyelitis and adoptive T cell transfer
colitis mouse models, and was associated with substantially reduced proinflammatory
cytokine release compared with an unbiased αCD3-TGF-β fusion protein control.**

**Details of the PosterTitle: A masked and TGFβRIII-biased αCD3-TGF-β fusion protein
promotes regulatory T cell induction and immune tolerance
Poster Number: POS-1110Track:
Basic and TranslationalTopic: Across diseasesSub-Topic: Adult Rheumatology

**Introduction:** T cell-mediated autoimmune diseases are characterized by sustained
activation of pathogenic effector T cells and insufficient or unstable regulatory
T cell function, resulting in an inability to establish durable immune tolerance.
These diseases remain an area of significant unmet medical need, as existing anti-
inflammatory therapies may not sufficiently eliminate persistent pathogenic effector
T cells or restore long-term immune balance. ATG-207 is designed to address these
challenges through a differentiated dual mechanism that integrates CD3-mediated 
T cell modulation with localized, TGFβRIII-biased TGF-β activity, with the goal 
of selectively suppressing pathogenic T cells while promoting regulatory T cell 
induction and immune tolerance.

**Mechanism of Action:** ATG-207 is designed to localize activity to T cells through
CD3 engagement while delivering controlled, TGFβRIII-biased TGF-β signaling. Its
dynamic masking is intended to reduce systemic receptor engagement and limit off-
target TGF-β activity. By preferentially engaging TGFβRIII over TGFβRII, ATG-207
promotes TGF-β responsiveness in T cells while potentially minimizing activity in
non–T cell compartments. This coordinated mechanism supports regulatory T cell induction
and attenuation of pathogenic T cell activity.

**Results: **ATG-207 showed preferential binding to TGFβRIII compared with TGFβRII
and significantly reduced T cell receptor (TCR) expression on the surface of primary
T cells. In healthy donor and systemic lupus erythematosus patient donor CD4+ T 
cells, ATG-207 demonstrated potent induced regulatory T cell activity, as measured
by FOXP3 expression. Proteomic profiling of primary T cells treated with ATG-207
showed evidence of T cell functional remodeling, including changes in pathways associated
with T cell signaling and immune regulation. _In vivo_, a mouse surrogate of ATG-
207 demonstrated therapeutic activity in both experimental autoimmune encephalomyelitis,
a multiple sclerosis model, and adoptive T cell transfer colitis, an inflammatory
bowel disease model. In human whole blood assays, ATG-207 induced minimal production
of pro-inflammatory cytokines, including IL-2, IL-6, TNF-α, and IFN-γ.

**Conclusion: **ATG-207 represents a differentiated immune tolerance–restoring strategy
that integrates precision T cell targeting, context-restricted TGF-β activity, and
TGFβRIII-biased signaling. The preclinical data support its potential as a next-
generation therapeutic approach for T cell–mediated autoimmune and inflammatory 
diseases.

**About Antengene **

Antengene Corporation Limited (**"Antengene"**, SEHK: 6996.HK) is a global, R&D-
driven, commercial-stage biotech company focused on developing first-in-class/best-
in-class therapeutics for diseases with significant unmet medical needs. Its pipeline
spans from preclinical to commercial stages, with key investigational candidates
including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 
x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-
TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed
using Antengene’s proprietary AnTenGager^(®) platform.

AnTenGager^(®) is Antengene’s proprietary TCE 2.0 platform, featuring "2+1" bivalent
binding for low expressing targets, steric hindrance masking, and proprietary CD3
sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) 
and enhance efficacy. These characteristics support the platform’s broad applicability
across autoimmune disease, solid tumors and hematological malignancies, with programs
targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered 
with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3(
ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer 
and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), 
GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid
leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute 
myeloid leukemia).

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the
U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific
markets. Its lead commercial asset, XPOVIO^(®) (selinexor), is approved in the Mainland
of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia,
Thailand, Indonesia and Australia, and has been included in the national insurance
schemes in five of these markets (Mainland of China, Taiwan China, Australia, South
Korea and Singapore).

**Forward-looking statements**

The forward-looking statements made in this article relate only to the events or
information as of the date on which the statements are made in this article. Except
as required by law, we undertake no obligation to update or revise publicly any 
forward-looking statements, whether as a result of new information, future events
or otherwise, after the date on which the statements are made or to reflect the 
occurrence of unanticipated events. You should read this article completely and 
with the understanding that our actual future results or performance may be materially
different from what we expect. In this article, statements of, or references to,
our intentions or those of any of our Directors or our Company are made as of the
date of this article. Any of these intentions may alter in light of future development.
For a further discussion of these and other factors that could cause future results
to differ materially from any forward-looking statement, please see the other risks
and uncertainties described in the Company’s Annual Report for the year ended December
31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald LungE-mail: [donald.lung@antengene.com](https://www.thailand-business-news.com/pr-news/donald.lung@antengene.com)

BD Contacts:
Ariel GuoE-mail: [ariel.guo@antengene.com](https://www.thailand-business-news.com/pr-news/ariel.guo@antengene.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Antengene Presented First Preclinical Data at EULAR 2026 Showing ATG-207 Promotes Regulatory T Cell Induction and Immune Tolerance ](http://www.prnasia.com/story/archive/4976835_AE76835_0?rand=184833)